New ISPOR Article Highlights Need for Clearly Defining Fit-For-Purpose RWD in Oncology Research, Reveals UReQA RWD Selection Framework
Fit-for-purpose real world data (RWD) is an attractive source of decision-making data. Multiple stakeholders, including regulatory affairs professionals and payers, [...]
On-Demand Cytel Webinar Highlights Basket Trials Using Oncology RWD
An on-demand webinar offered by Cytel details how information borrowing in basket trial studies can offer valuable insight. Basket trials [...]
NICE Upholds Rejection of Expensive Cancer Drug as Calls for Flexible Drug Pricing Models Grow
The National Institute for Health and Care Excellence (NICE) has rejected Zytiga for the second time. Despite evidence that the [...]
Updated FDA Guidance Recommends Inclusion of Patients with Incurable Cancers in Clinical Trials
The Food and Drug Administration (FDA) has issued draft guidance instructing clinical trial sponsors to include patients with incurable cancers [...]
Register Today for Upcoming ISPOR Webinar on Using RWD to Improve Oncology Research and Patient Outcomes in China
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will host a webinar on June 29th, 2021, at 11:00 AM [...]
Register Today for Upcoming Webinar on RWD in Oncology Drug Development
A webinar on using real world data (RWD) in the context of oncology drug development will feature insight from cancer [...]
[Cytel Whitepaper] How Can RWE Drive Oncology Drug Development?
Cytel has published a whitepaper detailing how real world evidence (RWE) can be used in cancer drug development, from preclinical [...]
Implementation of Magellan Rx Management Oncology Biosimilar Technology Leads to $40 Million in Annualized Savings
Magellan Rx Management announced that its customers have experienced annualized savings exceeding $40 million. The technology solution promotes the use [...]
Budget Oncology Drug Could Rival Top Lung Cancer Chemotherapies
A new drug created by Chinese CStone Pharmaceuticals and EQRx offers a low-cost alternative in the crowded lung cancer chemotherapy [...]
xCures Opens Artificial Intelligence xINFORM Platform Early to Inform Cancer Patient Care
xCures has announced early access for its xINFORM platform. The free platform is designed to identify personalized treatments for late-stage [...]
Innovent Biologics and Eli Lilly Submit Joint Low-Cost Lung Cancer Drug to FDA
Eli Lilly and Innovent Biologics have partnered to submit an application to the Food and Drug Administration (FDA) for a [...]
Cost-Saving Oncology Pathways Evaluation Tool Now Available
A comparison tool allows users to effectively evaluate oncology pathways. Results include better quality of care, less variability in care, [...]
FDA’s Accelerated Drug Approval Process Brings Questions and Uncertainty
The FDA’s Accelerated Approval program offers an avenue to improve research and access in instances where therapeutic options are limited. [...]
New Article Discusses 35 Oncology Drugs Receiving Accelerated Approval
An article published in the New England Journal of Medicine (NEJM) discusses 35 oncology drugs that received accelerated approval from [...]
FDA to Discuss Fates of Half a Dozen Cancer Drugs Next Week
The Food and Drug Administration has set a three-day meeting from April 27th to the 29th where a host of [...]
Phesi Partners with Accenture to Release Report on RWD in Drug Development
Analytics group Phesi partnered with Accenture to release the first of several reports on the use of RWD (real world [...]
Biologics by McKesson Launches Oncology Pharmacy Solution to Improve Access to Care
A new pharmacy management solution, ScriptPAS, has been launched by McKesson. The fee-for-service solution is expected to help improve medication [...]
The US FDA Has a Different Rubric for Cancer Drug Approval Than the UK and Canada
Different regulatory bodies have different criteria when it comes to drug approval, especially in the case of cancer drugs. The [...]
Syapse Invests $68 Million in Expanding RWE to Improve Outcomes for Cancer Patients
Leading RWE (real world evidence) company Syapse has invested $68 million in a venture with Ally Bridge Group and Northpond [...]
Meta-Analysis Study on Kidney Cancer Utilizes Novel Techniques to Identify Biomarkers
The survival rates of patients with kidney cancer largely depend on identifying biomarkers. The identification of these biomarkers can help [...]
xCures Announces Collaboration with CancerCompass
Today, xCures announced their collaboration with CancerCompass, allowing consumers who contact CancerCompass to access the xCures' platform and services.Consumers who [...]
ICER Publishes Final Evidence Report for Bladder Cancer Therapies
The Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and value of [...]
[Webinar] Tumor Profiling for Health Insurance Providers
On December 10, 2020 1:00 PM – 2:00 PM ET, Illumina will host a webinar on comprehensive genomic profiling (CGP). [...]
Jazz Pharmaceuticals Creates New Education Center for Rare Cancer Patients
Jazz Pharmaceuticals has launched Find the Right Fit, a new digital education hub focused on two rare blood cancer types—myelodysplastic syndrome [...]
Pathways for Regulatory and HTA of Histology Independent Therapies
Histology independent therapies represent a new era in personalized healthcare and drug development while challenging existing diagnostic and value assessment [...]